Texe Marrs - Face to Face with The Devil

Texe Marrs has done extensive and exhaustive research to present to you an in depth view coupled with a plethora of information on statues from around the world and their religious significance, many people literally admire, adore and worship these grotesque figures as if they somehow emit some form of energy force empowering the individual. Since the dawn of man, men have worshiped stone figures and have gone as far as to sacrifice people on altars to stone gods in hopes they will be given empowerment and or enlightenment.

(Please, I implore you to support and donate to Power of Prophecy Ministries if you can afford it, so Texe Marrs can have the resources to continue to expose the Illuminati satanic crime syndicate, your contributions will be greatly appreciated.)

Side note: "I have no affiliation with Texe Marrs in any way, just a fan of his work."

"I wanted to upload this video in "HD" (1gb) but it would have taken 12 hours to download each individual video that I ripped, my CPU is slow."

AP Survey: Economic Outlook Dim

AssociatedPress--October 28, 2010--A new AP Economy Survey suggests there's only modest improvement on tap for 2011.

Expert: QE2 Helps Bond Market

Dave Withrow of Fifth Third Asset Management on his outlook for the bond market and economy.

Baby Boomers in Piles of Debt

John Pottow, law professor at the University of Michigan, argues baby boomers' debt doubled due to credit cards.

The Pharma Industry: Pressure to Reduce Costs Suggests Collaboration

         

The past decade has not been the kindest from a business cycle perspective for several industries.  Globalization and the continual migration of growth centers around the planet have required corporations to be nimble footed, able to switch strategies and make mid-course corrections, not always an easy task when size hampers the process.  One case in point is the pharmaceuticals industry, where many large companies enjoyed value appreciation nearing 3-digit multiples from 1985 to 2000, but now are facing enormous pressure to modify their business models to be successful going forward.

Healthcare reform and the recession have slowed growth prospects appreciably.  Current forecasts for growth over the next five years are in the mid-single digit range as current products that account for nearly $142 billion in revenue for the industry will come off patent and be subjected to intense generic competition.  The introduction of new products is not expected to fill the gap, thereby causing revenue growth to stall.  Large companies, if they have not already done so, will have to resort to cost cutting and off-shoring activities to remain competitive.  By 2020, most industry pundits believe that industry-wide collaboration is the only viable course to pursue for continued growth and profitability.

Like many others, the pharmaceutical industry is also focusing on emerging markets for promising growth potential.  International talent will be necessary in all disciplines, not necessarily ones that have taken a forex course or practiced for hours on a forex demo account, but ones acquainted with developing complex distribution networks in foreign markets and coordinating testing protocols with local healthcare providers.  “BRIC”, an anagram for Brazil, Russia, India and China, will become enshrined in Big Pharma terminology.  China alone is expected to experience annual growth in the pharmaceutical sector in excess of 20% for years to come.  Growth from emerging markets will go a long way to offsetting losses from the “patent cliff” over the next five years.

Challenges over the next decade will center on the following issues:

·         Healthcare Reform:  More coverage equates to more prescriptions.

·         The Economy:  Cost cutting and M&A activity must be absorbed.

·         Pharmacy Reimbursements:  Local payment models need revision.

·         Research & Development:  Collaboration needed due to huge capital needs.

·         Regulation:  Carve-out legislation related to generic drugs may constrain.

·         Drug Safety:  Recent episodes demonstrate that test compromises exist.

·         Technology:  E-prescribing can eliminate time-consuming process aspects.

The Pharma industry has benefited by deploying a fully integrated business model that allowed it to act alone and profit very handsomely.  This model is being subjected to enormous pressure and must change in order to succeed in the years ahead.  If the industry is to truly improve its testing protocols, reduce overall costs, and serve consumers in emerging markets more effectively, it must learn to transition from only producing medicines to also managing outcomes.  Healthcare payers, providers and patients are demanding this expanded role.  Collaboration with other organizations offers a potential solution for the road ahead.

G-20: Diplomatic Defeat for U.S. Currency War Not Over

Oct. 25 (Bloomberg) -- Brendan Brown, chief economist at Mitsubishi UFJ Securities International Plc, talks about the Group of 20 meeting in Seoul and the outlook for Asian currencies and the dollar. He speaks with Maryam Nemazee on Bloomberg Television's "The Pulse."

Currency Tensions at G-20 - Jim Rogers

Oct. 22 (Bloomberg) -- Sebastien Galy, a currency strategist at BNP Paribas SA in New York, talks about expectations for this weekend's meeting of the Group of 20 finance chiefs in Gyeongju, South Korea. As G-20 financial leaders begin talks today, China is deflecting foreign pressure to fast-track the yuan's gains after limiting them to about 2 percent against the dollar since a June vow to embrace more flexibility. Galy speaks from New York with Rishaad Salamat on Bloomberg Television's "First Up."

Is the U.S. Economy Doomed to Another Crash?

Dylan Ratigan—Oct. 21, 2010—Panel debates whether the economic crisis in Paris and London are a preview of what's to come for America.

Full Spending Cuts Unveiled by U.K. Government

itnnews--October 20, 2010--George Osborne has laid out where the axe will fall to reduce the country's deficit.

Morgan Stanley CEO Vows No Job Cuts this Year

FBN's Charlie Gasparino on the bank's plans to not cut jobs despite a third-quarter loss.

Goldman Sachs Beats Estimates

FBN's Connell McShane breaks down the quarterly results for the bank.

Industrial Production Falls in September

FBN's Shibani Joshi breaks down the day's top stories.

50 States Investigating Foreclosure 'Robo-Signers'

Ohio Attorney General Richard Cordray debates the attorneys generals case into the validity of the foreclosure filings from around the country.

Wall Street immune to recession

Just two years after the global financial crisis that threatened to destroy the banking industry, Wall Street bonuses have hit a record high. According to The Wall Street Journal, employees at America's biggest banks are set to reward themselves with $144 billion in compensation and benefits this year. Karl Denninger of The Market Ticker believes that if you are a banker it seems you are immune to prosecution, originally under the Bush Administration and now under the Obama Administration.

Is the stock market rigged? Dylan Ratigan Show

Dylan Ratigan--October 11, 2010—Sen. Ted Kaufman talks about why new government rules are necessary for high frequency trading.

Mike Norman and Gasparino vs Roubini

Mike Norman who was famous for continually bashing Peter Schiff has now found another target in the other doctor Doom Nouriel Roubini

How Wall Street Shafted Main Street

CNN --October 11, 2010--Josh Rosner, who heads the research firm Graham Fisher, presents new proof that banks knew they were selling bad loans.

Banks Need to Unleash Money, Not Freeze Foreclosures says Mike Reagan

The Reagan Group Chairman Mike Reagan argues a freeze on foreclosures will not help the housing market

Financial Collapse Jim Willie 10-7-2010

Jim Willie interview with Miningstiocktalk.com 10-7-2010

Goldman predicts economy failing

Goldman Sachs says the US economy is going to be "fairly bad" with little growth or "very bad" going into recession. It's what a lot of people in the financial community have been saying for the last 6 months, so why are their comments making such a splash in the media, and what motives do they have in saying this now?

Mark Mobius : Deep correction quite possible before year-end

Global markets have been okay for the last few sessions but as we head towards the next expected round of quantitative easing there is a lot of debate building up on the West on what the quantum will beM-^Wwhether the size will be enough and whether it's desirable and will have the desired effect in the first place.

Unemployment to Rise?

A look ahead of tomorrow's jobs report.